nach oben

Erschienen in:

01.08.2012 | Original Paper

Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure

verfasst von: Tímea Gombos, Zsolt Förhécz, Zoltán Pozsonyi, Gábor Széplaki, Jan Kunde, George Füst, Lívia Jánoskuti, István Karádi, Zoltán Prohászka

Erschienen in: Clinical Research in Cardiology | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The purpose of this study was to evaluate complement activation in a heart failure cohort. Based on their powerful biological activity, we hypothesized that the levels of anaphylatoxin C3a are related to pathological signs and outcomes in heart failure.

Design, setting and patients

Complement activation products C3a and SC5b9 were determined in 182 consecutive CHF patients (single centre, prospective cohort study), with a left ventricular ejection fraction <45%. Mortality and re-hospitalisation due to the progression of CHF were assessed after a median follow-up of 14 months.

Interventions

None.

Results

In the univariate analysis, high level of anaphylatoxin C3a was significantly associated with clinical events (p < 0.0001), whereas SC5b9 showed a tendency of association (p = 0.094). In multivariable Cox analysis, adjusted for age, NT-proBNP, diastolic blood pressure, body mass index (BMI), haemoglobin and creatinine levels, C3a was a significant predictor of HF-related re-hospitalization or death (HR 1.189 per 1-SD increase, 95% CI 1.023–1.383), and of cardiovascular events or death (HR 1.302, CI 1.083–1.566). C3a was strongly associated with the presence of peripheral oedema, inflammatory markers (CRP, prealbumin, IL-6, sTNFRI, sTNFRII), heat-shock protein 70 levels and endothelial activation markers (von-Willebrand factor and endothelin-1).

Conclusions

Results of the present study showed that complement activation is strongly linked to unfavourable outcomes in heart failure. High levels of anaphylatoxin C3a predicted re-hospitalization, cardiovascular events and mortality in adjusted survival model. Increased C3a levels were associated with biomarkers of acute-phase reaction, inflammation, cellular stress response, endothelial-cell activation and oedematous complications independently from disease severity.

Celis R, Torre-Martinez G, Torre-Amione G (2008) Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy? Curr Opin Cardiol 23:254–260PubMedCrossRef

Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ (1997) Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79:1426–1430PubMedCrossRef

Rauchhaus M, Coats AJ, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930–933PubMedCrossRef

Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842PubMedCrossRef

Markiewski MM, Lambris JD (2007) The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171:715–727PubMedCrossRef

Harboe M, Mollnes TE (2008) The alternative complement pathway revisited. J Cell Mol Med 12:1074–1084PubMedCrossRef

Muller-Eberhard HJ (1988) Molecular organization and function of the complement system. Annu Rev Biochem 57:321–347PubMedCrossRef

Matsushita M (1996) The lectin pathway of the complement system. Microbiol Immunol 40:887–893PubMed

Guo RF, Ward PA (2006) C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov 1:57–65PubMedCrossRef

10.

Torre-Amione G (2005) Immune activation in chronic heart failure. Am J Cardiol 95:3C–8C discussion 38C–40CPubMedCrossRef

11.

Aukrust P, Gullestad L, Lappegård KT, Ueland T, Aass H, Wikeby L, Simonsen S, Frøland SS, Mollnes TE (2001) Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation 104:1494–1500PubMedCrossRef

12.

Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, Caulin-Glaser T, Daher E, Kosiborod M, Bell L, Setaro JF (2001) Serum complement activation in congestive heart failure. Am Heart J 141:684–690PubMedCrossRef

13.

Zwaka TP, Manolov D, Ozdemir C, Marx N, Kaya Z, Kochs M, Höher M, Hombach V, Torzewski J (2002) Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes. Am J Pathol 161:449–457PubMedCrossRef

14.

Zimmermann O, Kochs M, Zwaka TP, Bienek-Ziolkowski M, Höher M, Hombach V, Torzewski J (2007) Prognostic role of myocardial tumor necrosis factor-alpha and terminal complement complex expression in patients with dilated cardiomyopathy. Eur J Heart Fail 9:51–54PubMedCrossRef

15.

Czúcz J, Cervenak L, Förhécz Z, Gombos T, Pozsonyi Z, Kunde J, Karádi I, Jánoskuti L, Prohászka Z (2011) Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure. Clin Res Cardiol 100(7):587–594PubMedCrossRef

16.

Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 52:1144–1151PubMedCrossRef

17.

Cejka J (1984) Performance characteristics of a commercial kit for assay of factor viii-related antigen. Clin Chem 30:814–815PubMed

18.

Gombos T, Forhecz Z, Pozsonyi Z, Janoskuti L, Prohaszka Z (2008) Interaction of serum 70-kDa heat shock protein levels and HspA1B (+1267) gene polymorphism with disease severity in patients with chronic heart failure. Cell Stress Chaperones 13:199–206PubMedCrossRef

19.

Franke J, Zugck C, Wolter JS, Frankenstein L, Hochadel M, Ehlermann P, Winkler R, Nelles M, Zahn R, Katus HA, Senges J (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 101(1):1–10PubMedCrossRef

20.

Tanner H, Mohacsi P, Fuller-Bicer GA, Rieben R, Meier B, Hess O, Hullin R (2007) Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transpl 26:622–629CrossRef

21.

Clark AL, Loebe M, Potapov EV, Egerer K, Knosalla C, Hetzer R, Anker SD (2001) Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J 22:2275–2283PubMedCrossRef

22.

Loebe M, Gorman K, Burger R, Gage JE, Harke C, Hetzer R (1998) Complement activation in patients undergoing mechanical circulatory support. ASAIO J 44:M340–M346PubMedCrossRef

23.

Loebe M, Koster A, Sänger S, Potapov EV, Kuppe H, Noon GP, Hetzer R (2001) Inflammatory response after implantation of a left ventricular assist device: comparison between the axial flow MicroMed DeBakey VAD and the pulsatile Novacor device. ASAIO J 47:272–274PubMedCrossRef

24.

Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F (1999) Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99:649–654PubMedCrossRef

25.

Pye M, Rae AP, Cobbe SM (1990) Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 63:228–230PubMedCrossRef

26.

Beranek JT (1997) C-reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart J 18:1834–1836PubMedCrossRef

27.

Collard CD, Väkevä A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL (2000) Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 156:1549–1556PubMedCrossRef

28.

Knowlton AA, Eberli FR, Brecher P, Romo GM, Owen A, Apstein CS (1991) A single myocardial stretch or decreased systolic fiber shortening stimulates the expression of heat shock protein 70 in the isolated, erythrocyte-perfused rabbit heart. J Clin Invest 88:2018–2025PubMedCrossRef

29.

Tanonaka K, Yoshida H, Toga W, Furuhama K, Takeo S (2001) Myocardial heat shock proteins during the development of heart failure. Biochem Biophys Res Commun 283:520–525PubMedCrossRef

30.

Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A (2002) Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 105:685–690PubMedCrossRef

31.

Genth-Zotz S, Bolger AP, Kalra PR, von Haehling S, Doehner W, Coats AJ, Volk HD, Anker SD (2004) Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. Int J Cardiol 96:397–401PubMedCrossRef

32.

Prohászka Z, Singh M, Nagy K, Kiss E, Lakos G, Duba J, Füst G (2002) Heat shock protein 70 is a potent activator of the human complement system. Cell Stress Chaperones 7:17–22PubMedCrossRef

33.

Bauersachs J, Widder JD (2008) Endothelial dysfunction in heart failure. Pharmacol Rep 60:119–126PubMed

34.

Hindmarsh EJ, Marks RM (1998) Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 160:6128–6136PubMed

Titel: Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure
verfasst von: Tímea Gombos
Zsolt Förhécz
Zoltán Pozsonyi
Gábor Széplaki
Jan Kunde
George Füst
Lívia Jánoskuti
István Karádi
Zoltán Prohászka
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: Clinical Research in Cardiology / Ausgabe 8/2012
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-012-0432-6

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure